BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)

By Yahoo! Finance   |   1 month ago
BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML)

BMO Capital Markets maintained its "Outperform" rating on Tourmaline Bio, Inc. with a price target of $35, citing the market's overreaction to Phase II data for Paci. Despite concerns, BMO believes Paci's quarterly treatment could outperform competitors.

Read More

Did you find this insightful?